Background. Clinical recognition of tularemia is essential for prompt initiation of appropriate antibiotic treatment. Although fluoroquinolones have desirable attributes as a treatment option, limited data on efficacy in the US setting exist.
Tularemia is an uncommon but potentially severe zoonosis caused by the gram-negative coccobacillus Francisella tularensis [1] . In North America, human illness is caused by 2 subspecies: F. tularensis subsp tularensis (type A), and F. tularensis subsp holarctica (type B). The organism is highly infectious [2] and can be transmitted to humans through arthropod bites, contact with infected animal tissues, ingestion of contaminated food or water, and inhalation of contaminated aerosols generated through agricultural, laboratory, or landscaping activities [3] . Disease typically manifests as regional lymphadenopathy with or without skin or mucosal ulceration following percutaneous inoculation, or as pneumonia or systemic disease following inhalational exposure. Hematogenous dissemination can result in infection of distant anatomical sites, and the clinical course may be influenced by underlying medical conditions [4] . Prior to the advent of antibiotics, overall case fatality rates for tularemia caused by type A strains was 5% to 15%; current mortality is <2% among reported cases in the United States [5] .
In addition to its role as the cause of naturally occurring tularemia, F. tularensis has been designated a Category A select agent with potential for use as an agent of bioterrorism [6, 7] . Concern regarding bioterrorism has driven heightened disease surveillance efforts and raised important questions regarding antimicrobials for prophylaxis and treatment in mass casualty settings. At present only aminoglycosides, tetracyclines, and chloramphenicol have been approved for treatment of tularemia by the US Food and Drug Administration (FDA). Use of these drugs is complicated by the need for intravenous administration of aminoglycosides, treatment regimens of at least 2 weeks with tetracyclines, or serious side effects [8, 9] . Although not FDAapproved for the treatment of tularemia, fluoroquinolones are highly effective against F. tularensis in vitro [10] and have been used successfully to treat a small number of patients in Europe [11] . This clinical experience may not be fully applicable to North America, however, as only type B strains occur in Europe. [12] .
Missouri is a long-standing focus of tularemia in North America [13] . Brosius documented illness consistent with tularemia in Missouri as early as 1909 [1] . From 2000 through 2007, the average annual incidence in the state was 4 cases per 1 000 000 population, accounting for approximately one-fifth of all cases reported nationally [14] . To better define current clinical and epidemiological features of tularemia in Missouri, we conducted a detailed retrospective review and analysis of clinical records for patients reported to the state during 2000-2007. This assessment also provided an opportunity to evaluate outcomes of US patients who, for various reasons, received treatment with fluoroquinolones.
METHODS
Cases were ascertained through review of reports to the Missouri Department of Health and Senior Services (MDHSS) through the Missouri Health Surveillance Information System, the statewide reporting system for notifiable conditions. All cases categorized as confirmed or probable tularemia were included. Consistent with national surveillance case definitions, a confirmed case of tularemia was defined as clinically compatible illness in a patient from whom F. tularensis has been isolated in a clinical specimen or there was a ≥4-fold change in serum antibody titer to F. tularensis antigen. A probable case was defined as clinically compatible illness in a patient with an elevated serum antibody titer (without documented 4-fold or greater change) or detection of F. tularensis in a clinical specimen by fluorescent assay. We contacted the reporting provider associated with each of the cases by mail, telephone, or fax and requested access to medical records from at least 2 months before to at least 2 months after the reported date of diagnosis. Medical records included clinical notes, special investigations, prescription charts, and results of special investigations.
We reviewed all available paper-based and electronic clinical records pertaining to these cases from facilities throughout Missouri using a standard data collection form. We collected information on exposure history, demographic features, clinical presentation, treatment, and outcome. When large portions of data were missing from facility records, we contacted other physicians listed as care providers in the records to provide supplementary documentation. We categorized tularemia clinical forms as ulceroglandular, glandular, oculoglandular, oropharyngeal, typhoidal, or pneumonic based on physician diagnoses and clinical description in the patient records. In accordance with published guidelines for treatment, we defined a standard course of treatment as (1) aminoglycosides administered intravenously (gentamicin) or intramuscularly (streptomycin) for at least 10 days, (2) tetracyclines administered intravenously or orally for at least 14 days, or (3) chloramphenicol administered orally for at least 14 days; all of which are FDA-approved drugs for the treatment of tularemia. We defined a course of fluoroquinolone treatment as at least 10 days of ciprofloxacin or levofloxacin administered either intravenously or orally. We defined antibiotic treatment failure as persistence or recurrence of symptoms after completion of either standard or fluoroquinolone treatment. For the purpose of this report, we defined antibiotics other than the aforementioned FDA-approved treatments or fluoroquinolones as ineffective treatment for tularemia.
This study was conducted using anonymized data from reportable disease cases and as such we were granted human subjects exemption from the institutional review boards of the Centers for Disease Control and Prevention (CDC) and MDHSS.
We analyzed all data in Epi Info 3.3.2 and SAS 9.2 (SAS Institute, Cary, North Carolina) software with significance defined as P < .05. We compared attributes among patients by age group, tularemia type, and occurrence of complications after initial illness. Continuous variables were analyzed by Student t test and categorical variables by χ 2 or Fisher exact test.
RESULTS
Detailed medical records were available for 121 of 190 patients (64%) with tularemia reported to MDHSS between 2000 through 2007; 59 patients had confirmed and 62 probable tularemia. For the remaining 69 patients, the medical record was not available for review within the study period (n = 58), contained insufficient data for analysis (n = 7), or was inaccessible because the provider had relocated and could not be contacted (n = 4). Patients with and without available records were similar in age, sex, year of reporting, and residence. Among the 121 patients whose medical records were reviewed, 79 (65%) were male, and the median age was 37 years (range, 6 months to 92 years). A U-shaped age distribution was observed in both sexes, though more pronounced among males ( Figure 1 ). The majority of patients resided in southwestern (35%) and central (30%) Missouri. Seventy-eight percent of patients reported onset of symptoms between May and September ( Figure 2 ). Among 81 (67%) patients for whom exposure history was documented, tick bites were reported by ≥50% of patients with clinical forms other than pneumonic tularemia. Other reported exposures included cat bites, mowing grass, handling animal tissues, and exposures to agricultural aerosols or dust (Table 1) . No cases were associated with laboratory exposures. There were no regional or agerelated differences in relative frequency of exposures. The records of 49 adults included data on occupation; 19 (39%) were retired, 14 (29%) worked primarily indoors (eg, teaching and office work), and 11 (22%) worked primarily outdoors (eg, farming and logging). Data on the interval between a discrete exposure and the onset of symptoms were available for 16 patients (15 after tick exposures and 1 after a cat bite) and the median incubation period was 3 days (range, 1-9 days). Patients presented most commonly to an outpatient care provider (58%) or the emergency room (32%) after a median of 3 days of illness (range, 0-44 days). Seventy (58%) patients were admitted to hospital, for a median stay of 4 days (range, 1-27 days).
Patients presented most commonly with ulceroglandular (37%) and glandular (25%) forms of tularemia (Table 1) . Median age differed by clinical form; glandular and oculoglandular forms occurred in younger patients and pneumonic and typhoidal cases occurred in older patients (P = .0003). Patients were hospitalized more commonly with pneumonic (79%), typhoidal (75%), or oculoglandular tularemia (75%).
On examination, among 35 patients with glandular or ulceroglandular tularemia and well-documented descriptions of the site of lymphadenopathy, 16 (43%) had cervical or occipital, 11 (30%) axillary, and 8 (23%) inguinal lymphadenopathy. Lymph node size ranged from 1.5 cm to 7 cm in diameter. Among 68 patients with ulceroglandular, glandular, and oropharyngeal tularemia and a documented differential diagnosis, 46 (68%) were initially diagnosed with more common but clinically similar infections other than tularemia, particularly gram-positive lymphadenitis or cellulitis, cat-scratch disease, and Epstein-Barr virus infection. Those patients initially misdiagnosed were younger than those suspected of having tularemia (P = .02). Patients with pneumonic tularemia presented most frequently with complaints of fever (86%), cough (50%, including 1 patient reporting blood-stained sputum), and shortness of breath (43%). All pneumonic cases were initially diagnosed as community-acquired pneumonia caused by more commonly occurring bacteria.
Although 90% of patients overall gave a history of fever, only 19 of 53 (36%) had a documented fever of >38°C at their first medical encounter. Among patients for whom hematologic data were available, 19 of 76 (25%) were anemic, 40 of 83 (48%) had leukocytosis (defined as a white blood cell count of ≥10 000/μL), and 8 of 76 (11%) had thrombocytopenia (defined as a platelet count of <150 000/μL). Leukocytosis occurred more commonly among patients with pneumonic tularemia (69%) and thrombocytopenia occurred most commonly among those with typhoidal tularemia (38%). Radiographic findings for 14 patients with pneumonic tularemia included pulmonary infiltrates in 11 (79%) that were unilateral in 7 and bilateral in 4; pleural effusions in 4 (29%); and hilar lymphadenopathy in 2 (14%).
Among the 59 patients with confirmed cases of tularemia, 39 had positive cultures of F. tularensis and 20 were diagnosed on the basis of their clinical presentation and a 4-fold change in antibody titer (Table 1) . Among the 62 patients with probable tularemia, all were diagnosed on the basis of a single positive serology through tube or microagglutination and none by direct fluorescent antibody testing. For 35 of 39 patients (90%) with culture-positive specimens, culture results were available before suspicion of tularemia was documented in the patient record. Median turnaround time from sample collection to state laboratory confirmation was 7 days (range, 4-14 days) for 11 blood culture specimens for which information was available.
Data on antibiotic treatment were available for 109 patients, 99 (91%) of whom received at least 1 dose of an aminoglycoside, tetracycline, or fluoroquinolone. The median interval between symptom onset and first administration of an effective antibiotic was 13 days (range, 0-82 days) and did not differ by clinical form. Overall, 51 (47%) patients were prescribed aminoglycosides. The frequency of aminoglycoside use was higher in children (62%) than in adults (35%) (P = .006). Of 20 patients who received ≥10 days of gentamicin, 9 were treated with gentamicin alone or in combination with inappropriate antibiotics; among those, 1 (11%) experienced treatment failure. In addition, 8 patients were successfully treated on courses of gentamicin shorter than 10 days. Fifty-three (49%) patients were prescribed tetracyclines. Of 16 patients treated with ≥14 days of doxycycline, 13 were treated with doxycycline alone or in combination with inappropriate antibiotics and 2 (15%) of those had treatment failure. Five patients were successfully treated on doxycycline courses of <14 days.
In total, 45 patients were treated with fluoroquinolones: 29 with ciprofloxacin and 16 with levofloxacin. Among 20 patients treated with ciprofloxacin for ≥10 days, 8 were treated with a combination including aminoglycosides, tetracyclines, or chloramphenicol and 2 patients were successfully treated with ciprofloxacin after an incomplete course of tetracyclines. Of the 10 treated with ciprofloxacin alone or in combination with ineffective antibiotics (Table 2), 9 were successfully treated and 1 failed. In addition, 1 patient was successfully treated with only 8 days of ciprofloxacin and another was considered by the treating clinician to have failed treatment after only 7 days of ciprofloxacin. Among 5 patients treated with levofloxacin for ≥10 days, 3 were treated in combination with other effective antibiotics, 1 was successfully treated with levofloxacin after an incomplete course of tetracyclines, and 1 failed treatment and was subsequently successfully treated with intravenous gentamicin.
Overall, 120 of 121 patients recovered. Six patients developed severe respiratory or renal dysfunction during the course of illness. Fifteen of 81 patients (19%) with lymphadenopathy required incision and drainage of suppurated lymph nodes. The delay between onset of symptoms and commencement of an effective antimicrobial treatment was significantly longer in those with lymph node suppuration than those without (21 days vs 13 days, P = .01). Two patients with pneumonic tularemia developed loculated empyema and required surgical decortication. Five patients with primary ulceroglandular and 1 with glandular tularemia developed secondary systemic illness due to hematologic bacterial dissemination from the primary inoculation site. The single death occurred due to sepsis in a 79-year-old woman with ulceroglandular tularemia and underlying cardiovascular disease. All data are n/total (%) unless otherwise specified.
Abbreviations: bpm, beats per minute; IQR, interquartile range; NA, no data available; WBC, white blood cell.
DISCUSSION
Tularemia poses an ongoing challenge for clinicians, clinical microbiologists, and public health officials alike. Infection is widespread but rare, exposures are diverse, and the clinical spectrum is exceedingly broad [15, 16] . Consequently, the diagnosis of tularemia is frequently overlooked by clinicians, even in highly endemic areas such as Missouri. In more than half of the confirmed cases reported here, tularemia was apparently not suspected until after the incidental isolation of F. tularensis. The resulting delay in appropriate treatment prolonged morbidity and increased the risk of complications, especially lymph node suppuration. In this series, similar to an analysis of reported tularemia cases in Missouri from 1949 through 1965 [17] , the majority of cases occurred in males, in the southwestern and central counties, in the summer months, and were associated with tick exposures. However, the average number of tularemia cases from 1949 through 1965 was 32 per year, compared with the 24 per year observed more recently. Furthermore, the winter increase in cases, originally observed by Assal and colleagues [17] , is far less pronounced in the current series ( Figure 2 ). This may reflect changes in winter hunting activities or practices and an associated decrease in direct handling of animal carcasses in recent years.
Children with glandular tularemia were frequently misdiagnosed as having gram-positive lymphadenitis or cat-scratch disease, conditions that are treated with antibiotics ineffective against tularemia [18] , or with Epstein-Barr virus infection, for which management is largely supportive. Confusion with cat-scratch disease may be increased owing to the potential for transmission through domestic cat bites or scratches [19, 20] , further complicating clinical differentiation from cat-scratch disease because of overlapping seasonal distribution [21] . That patients with the "classic" presentation of ulceroglandular tularemia were not diagnosed or treated any sooner than patients with other clinical forms may indicate a lack of awareness about the disease among the provider community.
FDA-approved antimicrobials for the treatment of tularemia include aminoglycosides and tetracyclines. In this series, the 2 classes were each prescribed in about 50% of cases. Aminoglycosides require intravenous administration but are generally considered the more effective agents and the only readily available FDA-approved treatment for use in children [22] . Tetracyclines are affordable oral formulations that can be used on an outpatient basis. Unfortunately, tetracyclines are relatively contraindicated for treatment of children <8 years of age, and their use is associated with a higher rates of relapse [8] . Fluoroquinolones were used commonly in this series, although usually in combination with another antimicrobial effective against F. tularensis. Among the 10 patients treated with ciprofloxacin alone or in combination with ineffective antibiotics for ≥10 days, the uneventful recovery of 9 (90%) is at least as good as reported for tetracyclines [8] . These results provide further evidence that fluoroquinolones may provide a safe and effective alternative for treatment of tularemia with the advantage over aminoglycosides of oral administration and requiring a shorter course of therapy than tetracyclines. However, data on the effectiveness of fluoroquinolones in the United States to date have been limited to those collected in observational studies. Because certain subtypes of F. tularensis unique to the region are known to cause more severe disease and even death [23] [24] [25] , more systematic data are needed to inform locally appropriate therapeutic (and prophylactic) guidelines. Francisella tularensis is highly infectious when grown in culture and poses a risk of aerosol exposure to laboratory workers. Although no laboratory-acquired infections were noted in this study, the majority of the F. tularensis isolates were discovered coincidentally when specimens were sent in for routine culture. Laboratory staff who process specimens, particularly from endemic regions, should be aware that specimens may be infectious in the absence of clinical suspicion of tularemia and should exercise appropriate caution when handling cultures of potential tularemia specimens.
This study had several limitations. Although the patients for whom medical records could be reviewed were demographically similar to others reported during the same period [14] , there may have been other differences that we could not assess. Differences in clinical severity may be attributable to infections with different molecular subtypes of F. tularensis, all of which have previously been identified in clinical samples from Missouri [24] ; however, we could not control for these differences because we had only serologic and culture results available to us without molecular subtyping. The clinical data were collected for the first documented clinical encounter (where available), but this encounter may have occurred at variable times during the course of illness, limiting interpatient comparability. The definition of treatment failure was based on literature and presumed timing of clinical decision points for changing therapy; however, consensus on validated variables for such determination is lacking [26] . The timeframe for records reviews may have resulted in missing later episodes of disease recurrence. We assumed appropriate dosages for patient weight and age and focused solely on treatment duration. Finally, as is typical of retrospective record reviews, there was variable completeness of data in the clinical records.
Recognition of tularemia requires vigilance on the part of clinicians. Diagnostic sensitivity may be increased by collection of a pertinent exposure history, recognition of variations in clinical presentation, and judicious application of laboratory tests. This should decrease the delay to initiation of effective antimicrobial therapy, with a reduction in the incidence of secondary complications. Further research should address the need for more systematic information on the efficacy of fluoroquinolones for tularemia, preferably through a formal clinical trial.
Notes

